These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27059219)

  • 21. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
    Wright JD; Neugut AI; Wilde ET; Buono DL; Malin J; Tsai WY; Hershman DL
    J Clin Oncol; 2011 Sep; 29(25):3408-18. PubMed ID: 21810679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma.
    Horváth-Puhó E; Suttorp MM; Frederiksen H; Hoekstra T; Dekkers OM; Pedersen L; Cannegieter SC; Dekker FW; Sørensen HT
    Clin Epidemiol; 2018; 10():1371-1380. PubMed ID: 30310329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of hormonal contraceptives and infertility medications on the risk of venous thromboembolism, ischemic stroke, and cardiovascular disease in women.
    Ge SQ; Tao X; Cai LS; Deng XY; Hwang MF; Wang CL
    J Investig Med; 2019 Apr; 67(4):729-735. PubMed ID: 30478156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Warren JL; Brown ML
    J Natl Cancer Inst; 2007 Jul; 99(13):1050; author reply 1051-2. PubMed ID: 17596580
    [No Abstract]   [Full Text] [Related]  

  • 26. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
    Gao S; Ma JJ; Lu C
    Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
    J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
    [No Abstract]   [Full Text] [Related]  

  • 28. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
    Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
    PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
    Bian J; Chen B; Hershman DL; Marks N; Norris L; Schulz R; Bennett CL
    J Clin Oncol; 2017 Jun; 35(17):1945-1951. PubMed ID: 28441110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study.
    Brand JS; Hedayati E; Bhoo-Pathy N; Bergh J; Hall P; Humphreys K; Ludvigsson JF; Czene K
    Cancer; 2017 Feb; 123(3):468-475. PubMed ID: 27727456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study.
    Zahir MN; Shaikh Q; Shabbir-Moosajee M; Jabbar AA
    BMC Cancer; 2017 Jan; 17(1):57. PubMed ID: 28093087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
    J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
    Zhan P; Wang Q; Qian Q; Yu LK
    Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
    Tallman MS; Gray R; Bennett JM; Variakojis D; Robert N; Wood WC; Rowe JM; Wiernik PH
    J Clin Oncol; 1995 Jul; 13(7):1557-63. PubMed ID: 7602344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort.
    Du XL; Lairson DR; Begley CE; Fang S
    J Clin Oncol; 2005 Dec; 23(34):8620-8. PubMed ID: 16314624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ischemic Stroke and Risk of Venous Thromboembolism in the General Population: The Tromsø Study.
    Rinde LB; Småbrekke B; Mathiesen EB; Løchen ML; Njølstad I; Hald EM; Wilsgaard T; Brækkan SK; Hansen JB
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27821402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
    Smith RE
    Clin Breast Cancer; 2003 Oct; 4(4):273-9. PubMed ID: 14651772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of incident venous thromboembolism on risk of arterial thrombotic diseases.
    Lind C; Flinterman LE; Enga KF; Severinsen MT; Kristensen SR; Braekkan SK; Mathiesen EB; Njølstad I; Cannegieter SC; Overvad K; Hansen JB
    Circulation; 2014 Feb; 129(8):855-63. PubMed ID: 24270266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.